The overall Specific Aim of the Career Development Program (CDP) is to recruit and develop the careers of junior faculty members who are committed to translational research in prostate cancer, and, in well-justified cases, mid-level and senior investigators who are already established in another area of research who want to redirect their research focus to the field of prostate cancer. The future of prostate cancer research lies in the continued entry of creative and innovative investigators into the field and the development of basic and translational projects that solve areas of unmet need. Institutional support of these endeavors is also critical to advances in the field;therefore the Prostate SPORE's CDP is supplemented by institutional funds to allow for rapid funding of important new initiatives within the scope of our SPORE research goals. Institutional funding totaling $675,000 annually has been secured for SPORE project and core support, as well as to provide supplemental funds for the CDP budget, allowing for the SPORE program to support promising new investigators working in the field of prostate cancer translational research. The priority for funding will be those applicants with potential for an independent research career in the field of prostate cancer, and whose initiatives are considered of highest scientific merit and with translational potential and relevance to the overall research mission of the UCLA Prostate SPORE. After initial review by the CDP Selection Committee, the Executive Committee approves the funding line and determines priorities for use of the CDP funds. Annual funding for each project will be a minimum of $50,000, and a minimum of two CDP awards will be funded annually.
Prostate cancer is the most common cancer diagnosis and the second leading cause of cancer-related death in American men. The CDP plays a key role in recruiting and training exceptional scientific talent for translational research projects in prostate cancer.
|Chen, Changhao; Cai, Qingqing; He, Wang et al. (2016) An NKX3.1 binding site polymorphism in the l-plastin promoter leads to differential gene expression in human prostate cancer. Int J Cancer 138:74-86|
|Yan, Yunwen; Li, Zhen; Xu, Xiang et al. (2016) All-trans retinoic acids induce differentiation and sensitize a radioresistant breast cancer cells to chemotherapy. BMC Complement Altern Med 16:113|
|Hurley, Paula J; Sundi, Debasish; Shinder, Brian et al. (2016) Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. Clin Cancer Res 22:448-58|
|Faltermeier, Claire M; Drake, Justin M; Clark, Peter M et al. (2016) Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proc Natl Acad Sci U S A 113:E172-81|
|Liang, Pei; Henning, Susanne M; Schokrpur, Shiruyeh et al. (2016) Effect of Dietary Omega-3 Fatty Acids on Tumor-Associated Macrophages and Prostate Cancer Progression. Prostate 76:1293-302|
|Lee, John K; Phillips, John W; Smith, Bryan A et al. (2016) N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer Cell 29:536-47|
|Wang, Piwen; Henning, Susanne M; Magyar, Clara E et al. (2016) Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy. J Exp Clin Cancer Res 35:73|
|Hu, Yangyang; Dong, Xuecheng; Wang, Guangchun et al. (2016) Five-Year Follow-Up Study of Transurethral Plasmakinetic Resection of the Prostate for Benign Prostatic Hyperplasia. J Endourol 30:97-101|
|Park, Jung Wook; Lee, John K; Phillips, John W et al. (2016) Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. Proc Natl Acad Sci U S A 113:4482-7|
|Stoyanova, Tanya; Riedinger, Mireille; Lin, Shu et al. (2016) Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. Proc Natl Acad Sci U S A 113:E6457-E6466|
Showing the most recent 10 out of 279 publications